STOCK TITAN
  1. Home
  2. Sec-filings
  3. AKTX
  4. [EFFECT] Akari Therapeutics Plc SEC Filing

[EFFECT] Akari Therapeutics Plc SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 29, 2026 4:15 P.M.
Form: S-1
CIK: 0001541157
Company Name: Akari Therapeutics Plc
File Number: 333-292930

Source: View Original Filing on SEC EDGAR

Akari Therapeutics Plc

NASDAQ:AKTX

View AKTX Stock Overview →

AKTX Rankings

#6588 Ranked by Market Cap
N/A Ranked by Dividends

AKTX Latest News

Mar 18, 2026
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
Mar 17, 2026
Akari Therapeutics Announces ADS Ratio Change
Mar 13, 2026
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
Feb 26, 2026
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
Feb 23, 2026
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

AKTX Latest SEC Filings

Mar 17, 2026
[8-K] Akari Therapeutics Plc Reports Material Event
Mar 16, 2026
[Form 4] Akari Therapeutics Plc Insider Trading Activity
Mar 4, 2026
[SCHEDULE 13D/A] Akari Therapeutics Plc Amended Major Shareholder Report
Mar 4, 2026
[SCHEDULE 13D/A] Akari Therapeutics Plc Amended Major Shareholder Report
Mar 4, 2026
[SCHEDULE 13G/A] Akari Therapeutics Plc Amended Passive Investment Disclosure

AKTX Stock Data

6.67M
34.54M
Biotechnology
Pharmaceutical Preparations
Link
United States
TAMPA